Publications by authors named "Jianshan Liu"
Article Synopsis
- The tumor microenvironment (TME) significantly affects the success of treatments for hepatocellular carcinoma (HCC), specifically highlighting the role of tumor-associated endothelial cells (TECs) that influence tumor development and treatment response.
- A study using multi-omics profiling investigated different TEC subpopulations in HCC, uncovering a new subset, CXCL12 TECs, that suppresses immune responses by preventing T cell activation and attracting immune-suppressive cells.
- Targeting CXCL12 TECs with a bispecific antibody aimed at both CXCL12 and PD1 shows potential to enhance anti-tumor immune responses, representing a promising strategy to improve HCC immunotherapy outcomes.
Low-grade intraductal carcinoma of accessory parotid gland: a case report.
Hua Xi Kou Qiang Yi Xue Za Zhi
October 2022
Salivary low-grade intraductal carcinoma (LGIDC) is a rare tumor that mainly occurs in the parotid. Thus far, LGIDC originating from the accessory parotid gland has been rarely reported in domestic and foreign literature. This study reports a case of LGIDC of the accessory parotid gland and a brief summary of its clinical features, diagnostic points, and treatment by reviewing the literature, with the aim of providing a reference for clinical practice and further research.
View Article and Find Full Text PDFGlobally, hepatocellular carcinoma (HCC) is one of the most common causes of cancer-associated mortalities. The clinical outcome of HCC patients remains poor due to distant metastasis and recurrence. In recent years, growing evidences have confirmed that the coiled-coil domain-containing (CCDC) family proteins are involved in the progression of several diseases.
View Article and Find Full Text PDFArticle Synopsis
- SLC25A51 is a newly identified mitochondrial NAD transporter that is overexpressed in human hepatocellular carcinoma (HCC), linked to poor patient outcomes.
- The increase in SLC25A51 expression is partially due to the decrease of miR-212-3p and correlates with aggressive tumor characteristics.
- Manipulating SLC25A51 levels affects HCC cell growth and metastasis, and the underlying mechanism involves a shift in glucose metabolism, indicating its potential as a prognostic marker and therapeutic target in HCC.